ACAD Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.62 |
| 52 Week High | US$20.68 |
| 52 Week Low | US$14.15 |
| Beta | 0.43 |
| 1 Month Change | -8.48% |
| 3 Month Change | -10.93% |
| 1 Year Change | -9.77% |
| 3 Year Change | -38.94% |
| 5 Year Change | -61.17% |
| Change since IPO | 148.06% |
Recent News & Updates
Recent updates
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 03
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Feb 13Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
Jan 08Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Nov 27Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Targeted Campaigns And Pipeline Expansions Set To Revolutionize Growth In Neurological Treatment Market
Sep 09 Targeted and DTC campaigns for NUPLAZID aimed at Parkinson's disease psychosis are expected to notably increase patient starts, directly enhancing market share and revenue.Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19Shareholder Returns
| ACAD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | -3.1% | -0.9% |
| 1Y | -9.8% | -8.7% | 8.4% |
Return vs Industry: ACAD underperformed the US Biotechs industry which returned -8.7% over the past year.
Return vs Market: ACAD underperformed the US Market which returned 8.4% over the past year.
Price Volatility
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACAD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Managed Access Programs For Trofinetide Will Begin European Market Entry In 2025
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 654 | Catherine Owen Adams | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD fundamental statistics | |
|---|---|
| Market cap | US$2.72b |
| Earnings (TTM) | US$226.45m |
| Revenue (TTM) | US$957.80m |
12.2x
P/E Ratio2.9x
P/S RatioIs ACAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD income statement (TTM) | |
|---|---|
| Revenue | US$957.80m |
| Cost of Revenue | US$385.09m |
| Gross Profit | US$572.71m |
| Other Expenses | US$346.26m |
| Earnings | US$226.45m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 59.79% |
| Net Profit Margin | 23.64% |
| Debt/Equity Ratio | 0% |
How did ACAD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/02 07:17 |
| End of Day Share Price | 2025/04/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ACADIA Pharmaceuticals Inc. is covered by 35 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Ishan Majumdar | Baptista Research |
| Esther Lannie Hong | Berenberg |